Aerovate announces $67.6-69.6M cash dividend range for proposed merger; stockholder vote April 16

Jade Biosciences, Inc.

Cash dividend expected $67.6-69.6M in aggregate, based on estimated net cash prior to merger closing.
As of April 4, 2025, 28,985,019 shares of common stock outstanding.
Stockholders vote on merger at special meeting scheduled for April 16, 2025 at 9:00 a.m. ET.
Closing expected no later than April 30, 2025, subject to stockholder approval and other conditions.
Dividend expected to be a return of capital, not characterized as dividend for tax purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.